Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
autologous human tumor-derived HSPPC-96 · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| autologous human tumor-derived HSPPC-96 | DRUG | - |
Pre-Surgery Inclusion Criteria: * Primary-intact resectable renal cell cancer, without known distant metastasis and be scheduled to have surgery with curative intent; * Tumor size greater than or equal to 5 cm OR macroscopic nodes OR renal vein thrombus OR vena cava thrombus by radiologic evaluatio...
Autologous human tumor-derived HSPPC-96 is an investigational cancer vaccine being studied for renal cell carcinoma and follicular lymphoma. It is derived from a patient's own tumor tissue and is designed to stimulate an immune response against the cancer. The drug is currently in clinical development and is not approved by the FDA.
Autologous human tumor-derived HSPPC-96 is being developed by Agenus Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AGEN. The company is conducting clinical trials to evaluate the safety and effectiveness of this investigational therapy in oncology indications.
Autologous human tumor-derived HSPPC-96 is in Phase 2 clinical development for lymphoma. A Phase 3 trial for renal cell carcinoma has been completed. The drug remains investigational and has not received FDA approval. Clinical trials are ongoing to further assess its potential as a cancer treatment.
Autologous human tumor-derived HSPPC-96 has been studied in two completed clinical trials. NCT00033904 was a Phase 3 survival study in patients with kidney cancer, enrolling 650 participants. NCT00081809 was a Phase 2 safety and effectiveness study in patients with indolent lymphoma, enrolling 35 participants.
Yes, autologous human tumor-derived HSPPC-96 is also known as Oncophage. The Phase 3 trial NCT00033904, titled 'Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer,' evaluated this drug in renal cell carcinoma. The drug is an investigational personalized cancer vaccine developed by Agenus Inc.